https://www.globenewswire.com/news-release/2023/01/31/2598055/0/en/NFL-BIOSCIENCES-Very-successful-capital-increase-for-NFL-Biosciences-with-over-3-million-raised.html
https://www.globenewswire.com/news-release/2022/10/25/2540438/0/en/NFL-Biosciences-2022-first-half-business-and-earnings.html
https://athenapharmaceutiques.com/wp-content/uploads/2022/11/Inaugration-of-new-RD-Facility-in-India.pdf
https://athenapharmaceutiques.com/wp-content/uploads/2022/03/March-2022-Athenas-First-Market-Authorization-in-Brazil-with-Ondansetron-ODT.pdf
https://www.globenewswire.com/en/news-release/2022/02/02/2377867/0/en/NFL-BIOSCIENCES-co-development-agreement-for-a-drug-candidate-to-reduce-alcohol-consumption.html
https://athenapharmaceutiques.com/wp-content/uploads/2021/12/Athena-steps-up-its-RD-output-in-France-and-India.pdf
https://www.lefigaro.fr/societes/l-appel-a-l-aide-des-fabricants-de-medicaments-generiques-20211012
https://athenapharmaceutiques.com/wp-content/uploads/2021/12/Bisoprolol-Aspirin-Acquisition-Athena-Oct-2021-Final.pdf
https://athenapharmaceutiques.com/wp-content/uploads/2021/12/Final-Athena-IPS-approved-by-Korean-and-Taiwan-GMP-2021-february.pdf
https://athenapharmaceutiques.com/wp-content/uploads/2020/12/Levocetirizine-ODT-Launch-in-Russia.pdf